Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 28,190	$ 36,744	$ 94,689	$ 127,248
General and administrative	12,019	12,284	41,416	41,432
Change in fair value of contingent value rights	0	0	0	1,980
Loss from operations	(40,209)	(49,028)	(136,105)	(170,660)
Interest income	2,953	77	7,543	205
Interest expense	(2,541)	(1,922)	(7,336)	(5,074)
Other (expense) income, net	(1,677)	(3,143)	(4,550)	2,412
Loss before income taxes	(41,474)	(54,016)	(140,448)	(173,117)
Income tax expense (benefit)	(2,826)	(141)	(26,200)	(83)
Net loss	(38,648)	(53,875)	(114,248)	(173,034)
Other comprehensive (loss) income:
Foreign currency translation adjustment	(419)	(553)	1,241	(2,383)
Unrealized gain on available for sale securities, net of tax	252	0	1,035	0
Other comprehensive (loss) income	(167)	(553)	2,276	(2,383)
Total comprehensive loss	$ (38,815)	$ (54,428)	$ (111,972)	$ (175,417)
Net loss per ordinary share - basic (in dollars per share)	$ (0.40)	$ (0.57)	$ (1.20)	$ (1.86)
Net loss per ordinary share - diluted (in dollars per share)	$ (0.40)	$ (0.57)	$ (1.20)	$ (1.86)
Weighted average ordinary shares outstanding - basic (in shares)	96,648,110	94,327,914	95,589,181	92,994,990
Weighted average ordinary shares outstanding - diluted (in shares)	96,648,110	94,327,914	95,589,181	92,994,990